Skip to main content
. 2016 Feb 24;37(7):689–698. doi: 10.1097/MNM.0000000000000496

Fig. 3.

Fig. 3

The survival curves of 140 patients receiving first-line R-CHOP or CHOP therapy for newly diagnosed DLBCL. (a) Progression-free survival (PFS) of patients according to novel IPI score/SUVmax prognostic modeling (P=0.000); (b) overall survival (OS) of patients according to novel IPI score/SUVmax prognostic modeling (P=0.000). DLBCL, diffuse large B-cell lymphoma; IPI, International Prognostic Index; SUVmax, maximum standard uptake value.